Form 4: Arcutis CLO Masaru Matsuda Executes Stock Sale

Arcutis Biotherapeutics EVP and Chief Legal Officer Masaru Matsuda sold 8,256 shares of common stock via a 10b5-1 trading plan.

Summary

• Masaru Matsuda, EVP and Chief Legal Officer of Arcutis Biotherapeutics, sold a total of 8,256 shares of common stock on May 4, 2026.
• The sales were executed in two tranches: 7,372 shares at a weighted average price of $23.2696 and 884 shares at a weighted average price of $23.6106.
• The primary transaction was conducted under a Rule 10b5-1 trading plan adopted on June 5, 2025.
• The secondary transaction was executed to cover tax withholding obligations related to the vesting of Restricted Stock Units.
• The filing corrects a previous reporting error from March 3, 2026, which had overstated the reporting person's beneficial ownership by 1,987 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing; the insider sale is pre-planned and the correction of a clerical error is a standard regulatory requirement.

Positives

• The sale was conducted under a pre-established 10b5-1 trading plan, indicating the transaction was planned in advance rather than based on immediate non-public information.

Negatives

• The filing discloses a previous reporting error (scrivener's error) from March 2026 that resulted in an overstatement of beneficial ownership.

Risks

• Continued reliance on 10b5-1 plans for liquidity may signal ongoing divestment by key executives.

Future Outlook

The reporting person continues to operate under a 10b5-1 trading plan scheduled to conclude on September 4, 2026.

Management Comments

• The reporting person confirms the sale was effected pursuant to a 10b5-1 trading plan.
• The reporting person acknowledges a previous scrivener's error regarding beneficial ownership and provides the corrected total.

Industry Context

StockSavvy.ai notes that executive stock sales via 10b5-1 plans are standard practice in the biotech sector for liquidity and tax management, and this filing reflects routine administrative compliance rather than a shift in corporate strategy.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard governance practice for biotech executives to avoid potential insider trading allegations.
• The correction of a previous filing error is a standard regulatory compliance procedure.

Corporate Governance

Stakeholder Impact

• Shareholders should note the correction in reported insider ownership figures.

Next Steps

• Completion of the 10b5-1 trading plan by September 4, 2026.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Insider Trading, Form 4, Biotech, Executive Compensation